If current trends continue, cancer deaths may eventually surpass deaths from cardiovascular disease.
Prostate cancer is the most common form of cancer in men, affecting approximately one in every forty men. Unfortunately, nearly 250,000 men in the US will be diagnosed with prostate cancer this year. Fortunately, when diagnosed early, prostate cancer has a cure rate of over 90%. Currently, early detection relies on rectal examination and prostate-specific antigen (PSA) testing.
There’s a new prostate cancer screening test on the horizon. Professor Robert Getzenberg, Johns Hopkins School of Medicine, evaluated a new test that detects a recently discovered blood protein, ProstaMark® EPCA-2 (Early Prostate Cancer Antigen)*. Dr. Getzenberg found that found that EPCA-2 was more accurate detecting prostate cancer than the standard PSA test.
Comparison:
– elevated PSA level – 20% have prostate cancer
– normal PSA level – 15% have prostate cancer
– Positive EPCA-2 – 94% have prostate cancer
– Negative EPCA-2 – 3% have prostate cancer
Early diagnosis is good, but…
“If there was a race between treatment and prevention, treatment would always finish dead last.”
— Frank W. Eves MD
Did you know that prostate cancer prevalence varies widely across the world? Prostate cancer is least common in Asia and most common in the United States, leading many experts to conclude that diet plays a significant role. Consider downloading the ‘Nutrition and Prostate Cancer Guide’ from the Prostate Cancer Foundation’s Web Site.
* Onconome, Inc.